Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 98 | 123 | 107 | 103 | 96 |
| Accounts receivable | N/A | -87 | 615 | -71 | 171 |
| Other Working Capital | 215 | -33 | 1,526 | 3,675 | -1,881 |
| Other Operating Activity | -7,132 | -7,472 | -8,372 | -9,737 | -6,851 |
| Operating Cash Flow | $-6,819 | $-7,469 | $-6,124 | $-6,030 | $-8,465 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -155 | -46 | -3 | 0 | 0 |
| Sale Of Investment | N/A | N/A | 0 | 6,766 | 6,790 |
| Investing Cash Flow | $-155 | $-46 | $-3 | $6,766 | $6,790 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -65 | -103 | -104 | -102 | -100 |
| Common Stock Issued | 2,040 | 1,598 | 1,471 | 21,328 | 3,449 |
| Other Financing Activity | 0 | 0 | 375 | 63 | 343 |
| Financing Cash Flow | $1,975 | $1,495 | $1,742 | $21,289 | $3,692 |
| Exchange Rate Effect | 246 | 711 | -684 | 436 | -369 |
| Beginning Cash Position | 29,603 | 34,912 | 39,981 | 17,520 | 15,872 |
| End Cash Position | 24,850 | 29,603 | 34,912 | 39,981 | 17,520 |
| Net Cash Flow | $-4,999 | $-6,020 | $-4,385 | $22,025 | $2,017 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,819 | -7,469 | -6,124 | -6,030 | -8,465 |
| Capital Expenditure | -155 | -46 | -3 | N/A | N/A |
| Free Cash Flow | -6,974 | -7,515 | -6,127 | -6,030 | -8,465 |